Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas

American Journal of Hematology

Volumn 70, Issue 3, 2002, Pages 181-185

  Rohatgi, Nitin ^a   LaRocca, Renato V ^b   Bard, Vanessa ^a   Sethuraman, Gopalan ^a   Foon, Kenneth A ^c,d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Abgenix Inc   (United States)

Author keywords

Fludarabine; Follicular lymphoma; Sequential chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; PREDNISOLONE; REMISSION INDUCTION; VIDARABINE; VINCRISTINE;

EID: 0036085772     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10137     Document Type: Article

References (24)

1. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
3. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University
4. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
5. Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: Challenges and opportunities
6. Cure and follicular lymphoma
7. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multi-center study by the Groupe d'Étude des Lymphomes de l'Adulte
8. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma
9. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up - A report from the Eastern Cooperative Oncology Group
10. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
11. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial
12. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy
13. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes
14. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma
15. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma
16. Phase III study of doxorubicin (CHOP) compared with mitoxantrone (CNOP) in elderly patients with intermediate/high risk non-Hodgkin's lymphoma
17. Tumor size, sensitivity to therapy, and design of treatment schedules
18. Natural history of malignant lymphomas with divergent histologies at staging evaluation
19. Prognostic factors in follicular lymphomas
20. Rituximab as first-line treatment of patients with follicular lymphoma and a low-burden tumor: Clinical and molecular evaluation
21. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
22. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
23. CHOP chemotherapy plus ritaximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
24. Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma